Google has updated its policies on "dangerous products and services, as well as healthcare and drugs," allowing advertisements for marijuana and topical CBD products to be promoted in California, Colorado, and Puerto Rico in the United States.
Google did not provide a clear explanation for why it is limiting ads in these three distinct markets.
The company stated that CBD advertisements for entertainment products are still subject to limitations, including "supplements, food additives and inhalants." Additionally, according to policy revisions, header ads on YouTube (owned by Google) appear at the top of the main homepage on all devices and do not apply to marijuana and CBD products.
Google also stated that drugs approved by the Food and Drug Administration (FDA) can now be advertised in these jurisdictions. This rule change will only benefit one manufacturer, Jazz Pharmaceuticals, whose high-CBD Epidiolex is the only product of its kind that the agency has approved to date. Epidiolex is used to treat severe seizures in children and was approved by the FDA in 2020.
These changes were announced at the end of the year and will take effect on January 20th. Advertisers can start applying for Google certification from that date and the application form will be released.
Google has announced that it has signed a contract with LegitScript, an internet and payment compliance company based in Portland, Oregon. LegitScript provides certification in high-risk industries and serves as a credential exchange for determining product advertising eligibility. Only products certified by LegitScript are permitted to be promoted on the Google platform.
According to Google, individuals seeking to advertise on the platform must provide their product samples or THC tests, and provide third-party analysis certificates to LegitScript for verification.
In an industry where contaminated, substandard, or illegal products are still prevalent, it is more important than ever to assure consumers that the CBD products they are purchasing have undergone proper scrutiny," said Scott Ross, CEO of LegitScript.
This internet giant appears to be unnerved by the prospect of continuing to use CBD products internally. Such products have received warnings from the FDA, as various studies have shown contamination by solvents and heavy metals among other impurities. Delta-8 THC derived from cannabis produced via synthetic processes has been implicated in the death of a child in Virginia last year.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
